Cargando…
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials
IMPORTANCE: Current data identifying COVID-19 risk factors lack standardized outcomes and insufficiently control for confounders. OBJECTIVE: To identify risk factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection. DESIGN, SETTING, AND PARTICIPANTS: This secondary cross-protocol...
Autores principales: | Theodore, Deborah A., Branche, Angela R., Zhang, Lily, Graciaa, Daniel S., Choudhary, Madhu, Hatlen, Timothy J., Osman, Raadhiya, Babu, Tara M., Robinson, Samuel T., Gilbert, Peter B., Follmann, Dean, Janes, Holly, Kublin, James G., Baden, Lindsey R., Goepfert, Paul, Gray, Glenda E., Grinsztejn, Beatriz, Kotloff, Karen L., Gay, Cynthia L., Leav, Brett, Miller, Jacqueline, Hirsch, Ian, Sadoff, Jerald, Dunkle, Lisa M., Neuzil, Kathleen M., Corey, Lawrence, Falsey, Ann R., El Sahly, Hana M., Sobieszczyk, Magdalena E., Huang, Yunda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346130/ https://www.ncbi.nlm.nih.gov/pubmed/37440227 http://dx.doi.org/10.1001/jamanetworkopen.2023.23349 |
Ejemplares similares
-
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials
por: Turley, Christine B., et al.
Publicado: (2023) -
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
por: Lora, Alfredo J. Mena, et al.
Publicado: (2023) -
Risk of COVID-19 after natural infection or vaccination
por: Rick, Anne-Marie, et al.
Publicado: (2023) -
Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022) -
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
por: Follmann, Dean, et al.
Publicado: (2020)